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Abstract
Introduction Some patients with breast cancer develop local
recurrence after breast-conservation surgery despite
postoperative radiotherapy, whereas others remain free of local
recurrence even in the absence of radiotherapy. As clinical
parameters are insufficient for identifying these two groups of
patients, we investigated whether gene expression profiling
would add further information.
Methods We performed gene expression analysis
(oligonucleotide arrays, 26,824 reporters) on 143 patients with
lymph node-negative disease and tumor-free margins. A support
vector machine was employed to build classifiers using leave-
one-out cross-validation.
Results Within the estrogen receptor-positive (ER+) subgroup,
the gene expression profile clearly distinguished patients with
local recurrence after radiotherapy (n = 20) from those without
local recurrence (n = 80 with or without radiotherapy). The
receiver operating characteristic (ROC) area was 0.91, and
5,237 of 26,824 reporters had a P value of less than 0.001
(false discovery rate = 0.005). This gene expression profile
provides substantially added value to conventional clinical
markers (for example, age, histological grade, and tumor size) in
predicting local recurrence despite radiotherapy. Within the ER-
subgroup, a weaker, but still significant, signal was found (ROC
area = 0.74). The ROC area for distinguishing patients who
develop local recurrence from those who remain local
recurrence-free in the absence of radiotherapy was 0.66
(combined ER+/ER-).
Conclusion A highly distinct gene expression profile for patients
developing local recurrence after breast-conservation surgery
despite radiotherapy has been identified. If verified in further
studies, this profile might be a most important tool in the
decision making for surgery and adjuvant therapy.
Introduction
The addition of postoperative radiotherapy to breast-conserva-
tion surgery in patients with lymph node-negative breast can-
cer has been shown to reduce the 10-year risk of local
recurrence from 29.2% to 10% [1]. However, more than half
of the patients will never develop local recurrence whether
given radiotherapy or not and a small proportion of the patients
will develop local recurrence despite being given radiotherapy.
Besides tumor-involved margins, generally accepted risk fac-
tors for the development of local recurrence are young age
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been reported (for example, extensive intraductal component
[6], family history [7], lymphovascular invasion [2,8-10], lobular
cancer [11], and estrogen receptor-negative (ER-) status
[10]), but their clinical usefulness so far is limited. If the
patients who develop local recurrence despite radiotherapy
can be identified, other treatment strategies should be consid-
ered. No factor hitherto has been found to be clinically useful
for the identification of patients developing local recurrence
after radiotherapy.
Gene expression analyses have been found to be useful for
molecular subclassification of breast cancer and also have
shown promising results for predicting distant recurrence [12-
17]. Concerning prediction of local recurrence, only a few
studies have been reported. Cheng and colleagues [18] dem-
onstrated two sets of gene expression profiles to be associ-
ated with local recurrence after mastectomy. Today, however,
the majority of patients with breast cancer are operated on
with breast-conservation surgery. As conventional risk factors
for local recurrence after mastectomy differ from those after
breast-conservation surgery, these findings may not be appli-
cable when using less extensive surgery. Two recent studies
included only patients treated with breast-conservation sur-
gery: one was unable to find a distinguishing gene expression
profile [19], whereas the other could only separate patients
developing local recurrence after radiotherapy from patients
not developing local recurrence by means of a predefined
gene list, the wound-response signature [20]. This signature
has been suggested to provide a possible link between cancer
progression and wound healing and originally was defined as
the fibroblast core serum response [21]. The material in the
study by Nuyten and colleagues [20] was heterogeneous with
regard to margin status, ER status, lymph node status, adju-
vant systemic treatment (47% with and 53% without), and
radiotherapy (including both standard and boost treatment).
This heterogeneity might be the reason for not finding a signif-
icant gene profile in this study when using the whole set of
genes. As far as the importance of considering ER status in
gene expression analyses, today it is generally accepted that
ER+ and ER- breast tumors have remarkably distinct gene
expression profiles [22,23] and this subdivision of ER status
has been successfully applied when predicting distant recur-
rence [14,24].
Our study aimed at elucidating whether gene expression anal-
ysis is useful in predicting tumor sensitivity to radiotherapy and
capacity to develop local recurrence in a patient material
homogenous with regard to tumor-free margins, lymph node
status, and radiotherapy (only standard doses). A predictive
gene expression profile might impact the choice of both sur-
gery and radiotherapy. A hypothetical clinical routine scheme,
demonstrating three treatment options, is outlined in Figure 1.
After a preoperative analysis of the gene expression profile, the
first step is to identify the patients who will develop local recur-
rence despite radiotherapy. For this group, mastectomy might
be a better choice. The second step is to separate those
patients with no capacity to develop local recurrence and
therefore not in need of radiotherapy after breast-conservation
surgery from those with a capacity to develop local recurrence
and in need of radiotherapy.
Materials and methods
Patients
Study design, inclusion criteria, and sample collection
Frozen tumor samples were collected from patients represent-
ing the following four groups: (a) LR+RT+ (local recurrence
developed after radiotherapy), (b) LR-RT+ (no local recurrence
after radiotherapy), (c) LR+RT- (local recurrence developed, no
radiotherapy given), and (d) LR-RT- (no local recurrence, no
radiotherapy given). All patients were operated on with breast-
conservation surgery and axillary clearance with no lymph
node involvement, tumor size of less than or equal to 30 mm
(two patients had tumors measuring 32 and 40 mm, respec-
tively, and one was T2 without any further information on size),
tumor-free margins (>1 mm), no multicentricity, and with fro-
zen tumor tissue with good RNA quality available. Local recur-
rence was defined as the appearance of a new breast tumor
in the ipsilateral residual breast parenchyma in the overlying
skin or in the scar. Patients with recurrence in the contralateral
breast or with distant metastases prior or simultaneous to local
recurrence were excluded. In the first inclusion, 102 patients
from a randomized clinical trial in the South and West health
care regions in Sweden [25] and 19 patients from a popula-
tion-based cohort study with a nested case-control study
(Stockholm and South Sweden) [3,26] were included (Tables
1 and 2). To perform gene expression profiling in a more
homogenous material with regard to ER status and yet with a
sufficient number of cases in all four subgroups, 22 additional
ER+ tumors from the South-East and South health care
regions were included in a second inclusion (Tables 1 and 2).
The study was approved by the Ethics Committee at Lund
Figure 1
A hypothetical clinical routine scheme for the choice of surgery and radiotherapy after preoperative gene exp ession analysi
radiotherapy after preoperative gene expression analysis.Page 2 of 11
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Clinical and pathological characteristics of the 77 patients receiving radiotherapy, with or without the development of local 
recurrence
All LR+RT+ LR-RT+
Time to local recurrence, months n = 30 n = 47
Median
Range 50 -





Tamoxifen and chemotherapy 0 0
No adjuvant treatment 0 0
24 46
Inclusion 1 and 2 Inclusion 1 Inclusion 2 Inclusion 1
Menopause
Pre 12 5 13
Post 7 1 33
Not available 0 5 1
Age at operation, years
Median 48 47 57
Range 27–63 34–73 33–73
Size, millimeters
Median 14 15 15
Range 2–32 10–20 4–22
Not available 0 2a 0
Grade
1 3 3 22
2 8 6 13
3 7 1 10
Not available 1 1 2
Estrogen receptor
Positive 9 11 42
Negative 10 0 5
Progesterone receptor
Positive 5 9 31
Negative 13 2 11
Not available 1 0 5
Health care region
South 8 2 30Page 3 of 11
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characteristics and follow-up information were collected from
the patients' medical records.
Treatment
Postoperative radiotherapy with a median absorbed dose of
50 Gy (range 48 to 54 Gy) was given in 24 to 27 fractions in
one series to the remaining breast parenchyma. Adjuvant sys-
temic therapy was given to 16 patients (Tables 1 and 2).
Conventional factors
Histological grade was re-evaluated according to Elston and
Ellis [27]. ER and progesterone receptor content were ana-
lyzed routinely after primary operation with enzyme immu-
noassay according to kit instructions (Abbott Laboratories,
Diagnostics Division, Chicago, IL, USA) and expressed as
femtomoles per milligram of cytosol protein. Receptor values
greater than or equal to 25 fmol/mg protein were considered
positive.
Gene expression analysis
RNA was extracted from freshly frozen invasive breast tumors
as previously described [28]. The RNA quality was assessed
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA), and the RNA integrity number (RIN)
method [29] was used to validate the RNA quality. Twenty-one
samples were excluded due to RIN values of below 6. Labeling
and hybridization were performed as previously described
[28]. By means of Human Genome Oligo Set Version 2.1
(containing 21,329 70-mer probes) and Human Genome
Oligo Set Version 2.1 Upgrade 27 (containing 5,462 70-mer
probes), oligonucleotide arrays were produced by the Swe-
gene DNA Microarray Resource Centre, Lund University [30].
In inclusion step 1, probes were printed in duplicate, creating
55 K slides, and in inclusion step 2, in single, creating 27 K
slides.
Statistics
Wilcoxon rank sum tests, Sammon maps, and support vector
machine (SVM) classifications [31] were performed with the
statistical language R [32] using the libraries MASS (Sam-
mon) and e1071 (SVM). For the SVM, only genes with no
missing values were used. For the LR+RT+ versus LR-RT+/LR-
RT- groups, the numbers of genes with no missing values were
9,128, 13,362, and 8,834 for the ER+, ER-, and combined ER
groups, respectively. For the LR+RT- versus LR-RT- groups,
they were 11,209, 13,547, and 10,658, respectively. For the
wound-response genes, the corresponding numbers were 93,
120, and 91 for the LR+RT+ versus LR-RT+/LR-RT- groups and
105, 122, and 99 for the LR+RT- versus LR-RT- groups. Leave-
one-out cross-validation was used. When a sample was left
out, the SVM was trained on the remaining samples, and the
distance to the maximal margin hyperplane (the decision value)
was calculated for the left-out sample. A linear kernel was
used and the cost of constraints violation (C constant) was
fixed to one. No parameter tuning was performed even if the
use of another layer of cross-validation might have improved
the results. The goal of this study was to prove that gene
expression profiles can distinguish the groups, not to find the
optimal classifier. Actually, the optimal classifier does not even
need to be an SVM. We also minimized potential suspicions
about information leak by restricting the parameters of the
SVM to the default values of the R function svm. A receiver
operating characteristic (ROC) curve and area were calcu-
lated using the decision values. The expected average value of
the ROC area is 0.5 if there is no discrimination between the
groups. Due to random variations, ROC areas above 0.5 are
often obtained even when there is no discrimination between
the groups. To distinguish a real discrimination between the
groups from the case of no discrimination, a p-value was cal-
culated. A small p-value makes it unlikely that the ROC area
can be reconciled with the case of no discrimination. The p-
value was calculated by a permutation test. The local recur-
rence labels were shuffled randomly 1,000 times and the ROC
areas were found for the corresponding classifications. The P
value was calculated as the fraction of the 1,000 permutations
that had an ROC area larger than the real one. If the P value
was zero, the random ROC areas were fitted to a normal dis-
tribution and the area under the tail above the real ROC area
was used as the P value. The P value of the ROC area for the
case of a fixed test set (that is, no cross-validation) was calcu-
lated by a permutation test of the labels in the test set. Odds
ratios, confidence intervals of odds ratios, and P values of
odds ratios were calculated with the R function Fisher test,
which uses the conditional maximum likelihood estimator.
Gene Ontology
The Gene Ontology (GO) [33] OBO (open biomedical ontol-
ogies) file of 14 November 2006 was used. Gene annotation
was performed using ACID (Array Clone Information Data-
base), which is a publicly available web application that pro-
vides GO categories for genes [34]. A total of 6,841 GO
West 2 0 9
South-East 0 9 0
Stockholm 9 0 8
aOne T1 and one T2. LR-RT+ = no local recurrence after radiotherapy; LR+RT+ = local recurrence developed after radiotherapy.
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Clinical and pathological characteristics of the 77 patients receiving radiotherapy, with or without the development of local 
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Clinical and pathological characteristics of the 66 patients, not receiving radiotherapy, with or without the development of local 
recurrence
All LR+RT- LR-RT-
n = 22 n = 44








Tamoxifen and chemotherapy 1 0
No adjuvant treatment 18 39
Inclusion 1 and 2 Inclusion 1 Inclusion 1 Inclusion 2
Menopause
Pre 9 3 4
Post 13 30 2
Not available 0 0 5
Age at operation, years
Median 53 61 49
Range 44–73 45–70 40–62
Size, millimeters
Median 15 13 16
Range 7–30 6–40 10–26
Not available 0 0 0
Grade
1 4 13 5
2 10 9 3
3 5 8 3
Not available 3 3 0
Estrogen receptor
Positive 14 27 11
Negative 8 6 0
Progesterone receptor
Positive 15 17 11
Negative 7 14 0
Not available 0 2 0
Health care region
South 9 21 11Page 5 of 11
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process', or 'Molecular function' had at least one gene in com-
mon with our data. The genes were ranked according to their
Wilcoxon rank sum P value between LR+RT+ and LR-RT+/LR-
RT- groups in the ER+ group. A Wilcoxon rank sum test was
performed for each GO category to test for over-representa-
tion of genes toward the top of the ranked gene list using Cat-
map [35].
Results
Patients with a capacity to develop local recurrence 
despite radiotherapy
To identify this group of patients, we compared LR+RT+ versus
LR-RT+/LR-RT- groups. There was an association between the
LR+RT+ group and ER- status (odds ratio 6.8, 95% confidence
interval 2.0 to 24; P = 0.0007) (Table 3). In this analysis, only
the patients from the first inclusion were used, as the second
inclusion was made on ER and local recurrence status. Age
can also distinguish the LR+RT+ group. Histological grade was
marginally able to separate the LR+RT+ group from the LR-
RT+/LR-RT- group, whereas tumor size was not (Table 3).
After filtering the microarray data on low-quality spots and
missing values, 26,824 reporters remained, representing
16,895 unique genes. From a Sammon map of the gene
expression profiles of the 100 ER+ patients from both inclu-
sions, it was evident that the LR+RT+ and LR-RT+/LR-RT-
groups were well separated even without gene selection (Fig-
ure 2). For supervised classification, an SVM was used. The
areas under the receiver operating curve (ROC areas) were
0.91 (P = 9 × 10-6) within the ER+ group, 0.74 (P = 0.08)
within the ER- group (Figure 3), and 0.83 (P = 9 × 10-5) within
the combined ER+/ER- group (data not shown). The ER+ group
was by far the larger group, which could explain the superior
performance of the ER+ group compared with the ER- one.
Also, the classification performance was deteriorated by com-
bining ER+ and ER- in one SVM; it was preferable to use dis-
tinct SVMs for the two subpopulations (Figure 3). For the ER+
group, at 90% sensitivity (18 of 20 LR+RT+ correctly classi-
fied), the specificity was 87.5% (70 of 80 LR-RT+/LR-RT- cor-
rectly classified), and at 90% specificity (72 of 80 LR-RT+/LR-
RT- correctly classified), the sensitivity was 80% (16 of 20
LR+RT+ correctly classified).
West 13 10 0
South-East 0 0 0
Stockholm 0 2 0
LR-RT- = no local recurrence, no radiotherapy given; LR+RT- = local recurrence developed, no radiotherapy given.
Table 2 (Continued)
Clinical and pathological characteristics of the 66 patients, not receiving radiotherapy, with or without the development of local 
recurrence
Table 3
A comparison between the LR+RT+ and LR-RT+/LR-RT- subgroups
Factor LR+RT+ LR-RT+/LR-RT- P value
ER status, number
Negative 10 11
Positive 9 69 0.0007a
Median age, years
All 48 61 0.00004b
ER- subgroup 49.5 53 0.12




3 7 18 0.055a
Median tumor size, millimeters 15 15 0.95b
Only cases from inclusion 1 are included. aFisher exact test. bWilcoxon rank sum test. ER = estrogen receptor; LR-RT- = no local recurrence, no 
radiotherapy given; LR-RT+ = no local recurrence after radiotherapy; LR+RT+ = local recurrence developed after radiotherapy.Page 6 of 11
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whether the gene expression profiling has classification ability
beyond that of age in the ER+ subgroup. We constructed a
training set from the 77 patients who were either older than 50
years and in the LR-RT+/LR-RT- group or younger than 50
years and in the LR+RT+ group. The test set consisted of the
remaining 23 patients (for example, those who were either
younger than 50 years and in the LR-RT+/LR-RT- group or older
than 50 years and in the LR+RT+ group). The point is that the
test set chosen contains patients who behave exactly opposite
to the usual connection between age and local recurrence.
Applying an SVM, we obtained an ROC area of 0.88 (P =
0.002). Furthermore, we checked the influence of health care
regions by using the 68 samples from the South and South-
East health care regions as a training set and the 32 samples
from the West or Stockholm health care regions as a test set.
The specific split into health care regions was done to get a
reasonable amount of samples in LR+RT+ and LR-RT+/LR-RT-
groups in both the training and the test set. No optimizations
were performed in this regard. The ROC area of 0.87 (P =
0.002) shows that the classifier indeed works across health
care regions.
The wound-response signature genes, also known as the core
serum response genes [21], were shown to have the ability of
partially predicting local recurrence [20]. We mapped the
wound-response signature to our microarrays and performed
an SVM classification using only this signature. The ROC
areas were 0.75 (P = 0.007) within the ER+ group, 0.75 (P =
0.08) within the ER- group, and 0.61 (P = 0.10) within the
combined ER+/ER- group.
Differentially expressed genes
A Wilcoxon rank sum test between LR+RT+ and LR-RT+/LR-
RT- groups within the ER+ subgroup was performed for all
26,824 reporters. A clear over-representation of genes with
small P values was found; for example, there are 5,237 report-
ers with a P value below 0.001 corresponding to a Benjamini-
Hochberg [36] false discovery rate of 0.005. A heatmap of the
81 genes with a known gene name, no missing values, and a
Wilcoxon rank sum test P value between the LR+RT+ and LR-
RT+/LR-RT- groups of below 10-6 is shown in Figure 4. A GO
analysis was performed using Catmap [35]. A total of 6,841
GO categories belonging to 'Cellular component', 'Biological
process', or 'Molecular function' were included. At a false dis-
covery rate of 0.05, only the four categories of cytosolic ribos-
ome (sensu Eukaryota), eukaryotic 43S preinitiation complex,
eukaryotic 48S initiation complex, and cytosolic small ribos-
omal subunit (sensu Eukaryota) were significant.
Patients with no capacity to develop local recurrence
To identify this group of patients, we analyzed LR+RT- versus
LR-RT- groups. ER- status was weakly correlated with the
LR+RT- group (odds ratio 2.5, 95% confidence interval 0.6 to
11; P = 0.21) (Table 4). Young age was correlated with local
recurrence in the ER+ group (Table 4). Neither histological
grade nor tumor size had the power to separate the two
groups.
An SVM gene expression classifier yielded an ROC area of
0.66 (P = 0.04) within the combined ER+/ER- group. The ER-
and ER+ subgroups were too small to give a significant result
on their own, even though there was a tendency of discrimina-
tive power within the ER+ subgroup. (ROC area = 0.62; P =
0.14). For the wound-response signature, the ROC areas
were 0.64 (P = 0.10) in the ER+ group, 0.69 (P = 0.27) in the
ER- group, and 0.68 (P = 0.03) in the combined group.
Discussion
We have found a highly significant gene expression profile
associated with the development of local recurrence after
breast-conservation surgery despite postoperative radiother-
apy. If patients resistant to radiotherapy can be identified, they
should be candidates for alternative treatment strategies such
as mastectomy, other adjuvant treatments, and/or higher radi-
ation doses as local recurrence implies an increased risk of
both distant metastases and mortality [37-39]. So far, there
are no markers useful in the clinic for the identification of radio-
resistant breast cancer. We found both age and ER status to
be associated with local recurrence after radiotherapy. How-
ever, our gene expression signature provides substantially
added value to these factors and also to histological grade and
tumor size. A hybrid classifier of age and gene expression
Figure 2
A Sammon map of the 100 estrogen receptor-positive patients within the LR+RT+ group (red dots, 20 patients) and the LR-RT+/LR-RT- group (blue dots, 80 atients)
the LR+RT+ group (red dots, 20 patients) and the LR-RT+/LR-RT- group 
(blue dots, 80 patients). The Sammon map was performed with all 
26,824 reporters. Euclidean distance in log2 expression values was 
used as the distance measure. LR-RT- = no local recurrence, no radio-
therapy given; LR-RT+ = no local recurrence after radiotherapy; LR+RT+ 
= local recurrence developed after radiotherapy.Page 7 of 11
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Due to the sample size in this study, we did not have the pos-
sibility to build such a hybrid classifier. We have focused on
the question of whether gene expression analysis per se is
useful for the identification of patients with different risks of
developing local recurrences. A thorough and more specific
evaluation of the gene list should be performed after a confirm-
ative study in which not only the genes, but also the pathways
in which they are involved, are considered. The high proportion
of ribosomal-related genes is noteworthy but also needs to be
confirmed. The samples were collected from four health care
regions with different routines for handling fresh tumor tissue
prior to freezing. However, we could clearly demonstrate that
these differences did not influence the importance of the gene
expression signature.
To our knowledge, only one previous study has reported a
gene expression signature significantly associated with local
recurrence after breast-conservation surgery [20], but only
when using a predefined wound-response signature gene list.
One reason for not finding a significant profile when using the
entire gene set may be that their material, which included 17
local recurrences, was more heterogeneous than ours with
regard to tumor-free margins, tumor size, lymph node status,
and dose of radiotherapy. Furthermore, they did not separate
the samples with regard to ER status. ER+ and ER- breast
tumors are known to have distinct gene expression profiles
and indeed we found a stronger gene expression profile when
including only ER+ tumors compared with when ER- tumors
were included (ROC area 0.91 compared with 0.83). This
finding further strengthened the notion that ER+ and ER- breast
cancer should be handled as two separate entities when eval-
uating gene expression data, as has previously been stated by
authors in analyses of gene expression profiles associated
with distant metastases [14,24,40]. In our material, the
wound-response signature genes were able to predict local
recurrence within both the ER+ group and ER- group with rea-
sonable accuracy, whereas the prediction in the combined
group was rather weak. For the ER+ group and the combined
group, the classification performance is inferior to the results
obtained with all genes. This degradation of performance
shows that the advantage of restricting the gene set used in
the classifier to the focused set of wound-response signature
genes, which are known to be relevant to cancer, is out-
weighed by the loss of information of discarding the majority of
the genes. The reason that the SVM using all genes was so
much better at classifying the combined group than the
wound-response signature genes is probably that the ER sig-
nal is contained in the full gene set but is more or less absent
in the wound-response signature genes. With respect to indi-
vidual samples, it is seen that the samples that were misclas-
sified with all genes were also misclassified with the wound-
response signature genes but that many of the misclassified
samples with the wound-response signature genes were cor-
rectly classified with all genes.
For the identification of patients with no capacity to develop
local recurrence, we compared the LR+RT- and LR-RT- sub-
groups. The gene expression signal was weaker, but still sig-
nificant (ROC area = 0.66). The reason for a weaker signal
Figure 3
Receiver operating characteristic (ROC) curves for the support vector machine classification of LR+RT+ versus LR-RT+/LR-RT- groups within the estrog n recep or-positive (ER+) group (left part) and trogen receptor-negative (ER-) group (right part)
estrogen receptor-positive (ER+) group (left part) and estrogen receptor-negative (ER-) group (right part). The specificity is defined as the fraction of 
the LR-RT+/LR-RT- patients correctly classified, and the sensitivity as the fraction of the LR+RT+ patients correctly classified. LR-RT- = no local recur-
rence, no radiotherapy given; LR-RT+ = no local recurrence after radiotherapy; LR+RT+ = local recurrence developed after radiotherapy.Page 8 of 11
(page number not for citation purposes)
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response genes, there is a tendency for correct predictions,
but the results are too weak to draw any conclusions. More
samples would be needed to test it further.
Today, the vast majority of breast cancer patients are treated
with radiotherapy after breast-conservation surgery to lower
the risk of local recurrence. However, a large proportion of
these patients have a very low risk for local recurrence, and the
positive effects must be weighed against costs and side
effects of the treatment. The identification of patients with a
very low risk to develop local recurrence, and consequently
not in need of postoperative radiotherapy, is of great clinical
importance.
No patient included in our study had tumor-involved margins,
a risk factor for local recurrence. The local recurrence rate is
influenced by the amount of uninvolved breast parenchyma
surrounding the tumor as higher recurrence rates have been
reported after lumpectomy [41] than after sector resection
[25] or quadrantectomy [42]. With smaller resection margins,
microscopic residual tumor is more likely to be present in the
breast and the administered radiotherapy dose may be too low
to give complete protection for local recurrence. Thus, it can-
not be excluded that the gene expression profile can be influ-
enced by resection margins.
Our gene expression profile was associated with local recur-
rence after radiotherapy at commonly used doses. Higher
doses of radiation, with a boost of 16 Gy, have been shown to
significantly reduce the local recurrence rate, particularly in
patients below 50 years of age [43]. Unfortunately, higher radi-
ation doses cause a less satisfactory cosmetic result [44].
Whether gene profiling also can be used for identification of
patients in need of a boost is unclear at present.
One might speculate why the gene expression profile method
performs significantly better for the prediction of local recur-
rence than for the prediction of distant metastasis. It is possi-
ble that the gene profile associated with the development of
Figure 4
The 81 most important genes. A heatmap of 81 genes (rows) and 100 patients (columns) with patients ordered according to their leave-one-out 
support vector machine classification value: estrogen receptor-positive patients within LR+RT+ (red, n = 20) and LR-RT+/LR-RT- (blue, n = 80) 
groups. The gene selection and ordering are described in the text. Expression values are logarithmically transformed, centered around zero, and nor-
malized to unit standard deviation. LR-RT- = no local recurrence, no radiotherapy given; LR-RT+ = no local recurrence after radiotherapy; LR+RT+ = 
local recurrence developed after radiotherapy.Page 9 of 11
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ance) is more homogeneous than the one associated with dis-
tant recurrences. It is believed that the development of
metastases is a more complicated process and that different
groups of genes may be of variable importance in distin-
guished subgroups of breast cancer.
Conclusion
We have found a very promising gene expression profile for
predicting local recurrence despite radiotherapy – a profile
that might be associated with radio-resistance. The signature
provides substantially added value to the conventional factors
used to predict risk of local recurrence. If confirmed in further
studies, this profile might be a most important tool in the deci-
sion making for type of surgery and adjuvant therapy.
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